ClinicalTrials.gg
RecruitingNCT07279194Updated Dec 12, 2025

Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes

A Phase 3 interventional study of HDM1005 1 and HDM1005 2 in Obesity & Overweight, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
825
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Obesity by Huadong Medicine Co., Ltd. — 10 open to participants now, 11 under way, 5 of them phase 3. Obesity · Huadong Medicine Co., Ltd..

Planned enrollment
Largest of 13
825 · median 200
Started
2025
with 3 others
Phase 3
5 of 13
5 open now
Primary completion
2026-09
later than 5 of 10 live
Registered
7th of 13
by date

Among the 13 studies in Obesity by Huadong Medicine Co., Ltd., this one has the largest planned enrollment, is one of 4 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 5 of the 10 other live ones, and was the 7th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

10 of the 13 studies in Obesity by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Obesity by Huadong Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy andsafety of the HDM1005 in patients with obesity or overweight. Eligible participants will be screened and randomized to different dose group of HDM1005 or the placebo group at a ratio of 1:1:1 , HDM1005 or placebo will be given once weekly for 52 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.

03

Conditions studied

  • Obesity & Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged ≥18 years at the time of signing .
  2. ≥28 kg/m2 or ≥24 kg/m2 and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, pre-diabetes, obstructive sleep apnea, fatty liver, weight-bearing joint pain.
  3. A self-reported change in body weight no more than 5% within 90 days before screening.
  4. Able to understand the procedures and methods of this study, willing to strictly comply with the clinical trial protocol to complete this trial, and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Have type 1 diabetes mellitus (T1DM) or T2DM.
  2. Have ≥6.5% or fasting serum glucose (FSG)≥7.0 mmol/L at Visit 1.
  3. Have obesity induced by other endocrinologic disorders (for example, Cushing syndrome) or by other medicine.
  4. Use of GLP-1 receptor (GLP-1R) agonists or GLP-1R/GCGR agonists or GIPR/GLP-1R agonists or GIPR/GLP-1R/GCGR agonists within 3 months prior to screening.
  5. Use of hypoglycemic drugs within 3 months prior to screening.
  6. History of thyroid C-cell carcinoma, multiple endocrine neoplasia (MEN) 2A or 2B or relevant family history.
  7. Previous history of acute and chronic pancreatitis, acute gallbladder disease history (except cholecystectomy) history.
  8. PHQ questionnaire ≥ 15 points at screening or randomization.
  9. Have had a history of moderate to severe depression; Or have a history of severe mental illness in the past.
  10. Uncontrolled hypertension prior to screening, defined as: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg (stable for 1 month if using antihypertensive drugs).
  11. History of (except cured basal cell carcinoma) in the past 5 years or at the time of screening.
  12. History of severe cardiovascular or cerebrovascular diseases within the past six months.
  13. History of alcohol and drug abuse at screening.
  14. The participant may be allergic to ingredients in the study drug or drugs of the same class.
  15. Pregnant or lactating females, males or females of not willing to use throughout the study.
  16. The subject has any other factors that may affect the efficacy or safety evaluation of this study, and is not suitable for participation in this study in the opinion of the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
825 participants (estimated)

Study arms

  • Experimental
    HDM1005 Cohort 1

    Drug: HDM1005 1

  • Experimental
    HDM1005 Cohort 2

    Drug: HDM1005 2

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.

  • Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose. The intervention will last for 52 weeks in total.

  • DrugPlacebo

    Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose. The intervention will last for 52 weeks in total.

06

What researchers measure

Primary outcomes

  1. primary outcome

    The percentage change in body weight from baseline to week 40

    Time frame: week 40

  2. Co-primary outcome

    Proportion of subjects with body weight reduction ≥ 5% at Week 40.

    Time frame: week 40

Secondary outcomes

  1. secondary outcome

    The proportion of participants reaching a body weight loss of at least 10% and 15% at week 40

    Time frame: week 40

  2. secondary outcome

    Change in waist circumference, body weight and BMI at week 40

    Time frame: week 40

  3. secondary outcome

    Change in waist circumference, body weight and BMI at week 52

    Time frame: week 52

  4. secondary outcome

    Change in systolic blood pressure (SBP), diastolic blood pressure (DBP) and lipids at week 40

    Time frame: week 40

  5. secondary outcome

    Change in SBP, DBP and lipids at week 52

    Time frame: week 52

  6. safety outcome

    the incidence of adverse events

    Time frame: week 52

  7. patient report outcome

    36-Item Short Form Health Survey, Version 2 questionnaire (scores range from 0 to 100, with higher scores indicating better health status) after administration for 52 weeks.

    Time frame: week 52

  8. Immunogenicity outcome

    ADA and NAb

    Time frame: week 52

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 11 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 12, 2025
StartActual
Oct 14, 2025
Primary completionEst.
Sep 20, 2026
CompletionEst.
Dec 13, 2026
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07279194
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Oct 14, 2025
Primary completion
Sep 20, 2026 (estimated)
Completion
Dec 13, 2026 (estimated)
Last update
Dec 12, 2025

Study contacts

Hui Qiao
Contact
qiaohui@eastchinapharm.com
+86 0571-89908523
Xiaoying Li
principal investigator · Shanghai Zhongshan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDM1005

Start the discussion